TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Obesity Prescription Drugs Market - By Mechanism of Action
1.3.2 Anti-Obesity Prescription Drugs Market - By Drug Class
1.3.3 Anti-Obesity Prescription Drugs Market - By Distribution Channel
1.3.4 Anti-Obesity Prescription Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-OBESITY PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MECHANISM OF ACTION
7.1. OVERVIEW
7.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
7.3. PERIPHERALLY ACTING DRUGS
7.3.1. Overview
7.3.2. Peripherally Acting Drugs Market Forecast and Analysis
7.4. CENTRALLY ACTING DRUGS
7.4.1. Overview
7.4.2. Centrally Acting Drugs Market Forecast and Analysis
8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. BUPROPION AND NALTREXONE
8.3.1. Overview
8.3.2. Bupropion and Naltrexone Market Forecast and Analysis
8.4. ORLISTAT
8.4.1. Overview
8.4.2. Orlistat Market Forecast and Analysis
8.5. LORCASERIN
8.5.1. Overview
8.5.2. Lorcaserin Market Forecast and Analysis
8.6. PHENTERMINE AND TOPIRAMATE
8.6.1. Overview
8.6.2. Phentermine and Topiramate Market Forecast and Analysis
8.7. LIRAGLUTIDE
8.7.1. Overview
8.7.2. Liraglutide Market Forecast and Analysis
9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-Obesity Prescription Drugs Market Overview
10.1.2 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.1.3 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.1.4 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.1.5 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-Obesity Prescription Drugs Market
10.1.6.1.1 United States Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.1.2 United States Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.1.3 United States Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.2 Canada Anti-Obesity Prescription Drugs Market
10.1.6.2.1 Canada Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.2.2 Canada Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.2.3 Canada Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.3 Mexico Anti-Obesity Prescription Drugs Market
10.1.6.3.1 Mexico Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.3.2 Mexico Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.3.3 Mexico Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Anti-Obesity Prescription Drugs Market Overview
10.2.2 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.2.4 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-Obesity Prescription Drugs Market
10.2.6.1.1 Germany Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.1.2 Germany Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.1.3 Germany Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.2 France Anti-Obesity Prescription Drugs Market
10.2.6.2.1 France Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.2.2 France Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.2.3 France Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.3 Italy Anti-Obesity Prescription Drugs Market
10.2.6.3.1 Italy Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.3.2 Italy Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.3.3 Italy Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.4 Spain Anti-Obesity Prescription Drugs Market
10.2.6.4.1 Spain Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.4.2 Spain Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.4.3 Spain Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Anti-Obesity Prescription Drugs Market
10.2.6.5.1 United Kingdom Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.5.2 United Kingdom Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.5.3 United Kingdom Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Anti-Obesity Prescription Drugs Market
10.2.6.6.1 Rest of Europe Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.6.2 Rest of Europe Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.6.3 Rest of Europe Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-Obesity Prescription Drugs Market Overview
10.3.2 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.3.4 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-Obesity Prescription Drugs Market
10.3.6.1.1 Australia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.1.2 Australia Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.1.3 Australia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.2 China Anti-Obesity Prescription Drugs Market
10.3.6.2.1 China Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.2.2 China Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.2.3 China Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.3 India Anti-Obesity Prescription Drugs Market
10.3.6.3.1 India Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.3.2 India Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.3.3 India Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.4 Japan Anti-Obesity Prescription Drugs Market
10.3.6.4.1 Japan Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.4.2 Japan Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.4.3 Japan Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.5 South Korea Anti-Obesity Prescription Drugs Market
10.3.6.5.1 South Korea Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.5.2 South Korea Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.5.3 South Korea Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.6.2 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Overview
10.4.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.4.4 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-Obesity Prescription Drugs Market
10.4.6.1.1 South Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.1.2 South Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.1.3 South Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Anti-Obesity Prescription Drugs Market
10.4.6.2.1 Saudi Arabia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.2.2 Saudi Arabia Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.2.3 Saudi Arabia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.3 U.A.E Anti-Obesity Prescription Drugs Market
10.4.6.3.1 U.A.E Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.3.2 U.A.E Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.3.3 U.A.E Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.4.2 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-Obesity Prescription Drugs Market Overview
10.5.2 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.5.4 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-Obesity Prescription Drugs Market
10.5.6.1.1 Brazil Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.1.2 Brazil Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.1.3 Brazil Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.2 Argentina Anti-Obesity Prescription Drugs Market
10.5.6.2.1 Argentina Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.2.2 Argentina Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.2.3 Argentina Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market
10.5.6.3.1 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.3.2 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.3.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, KEY COMPANY PROFILES
13.1. BRISTOL-MYERS SQUIBB CO.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. TAKEDA PHARMACEUTICAL
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. EISAI COMPANY
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PFIZER INC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SHIONOGI USA INC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. VIVUS INC
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ZAFGEN INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NORGINE BV
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BOEHRINGER INGELHEIM GMBH.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. BRISTOL-MYERS SQUIBB CO.
2. TAKEDA PHARMACEUTICAL
3. EISAI COMPANY
4. GLAXOSMITHKLINE PLC
5. PFIZER INC
6. SHIONOGI USA INC
7. VIVUS INC
8. ZAFGEN INC
9. NORGINE BV
10. BOEHRINGER INGELHEIM GMBH.
11. 7TM PHARMA
12. ZYDUS CADILA
13. AKRIMAX PHARMACEUTICALS
14. ZEALAND PHARMA
15. ARROWHEAD RESEARCH
Get the Latest COVID-19 Analysis on this market